Aclaris Therapeutics, Inc. - Common Stock (ACRS)
2.5400
+0.1500 (6.28%)
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological and immunological diseases
The company is committed to addressing unmet medical needs by leveraging its expertise in drug development and dermatology to create novel treatment options. Aclaris's research portfolio includes a range of potential therapies aimed at conditions such as alopecia areata and other skin disorders, utilizing both small molecules and biologics to enhance patient care and improve quality of life. Through its dedication to scientific advancement and patient-centered approaches, Aclaris strives to make a meaningful impact in the field of dermatology.
Santa Rally, January Effect, And Top Stock Pickstalkmarkets.com
Explore December 23's top pre-market picks, macro insights, and Santa Rally opportunities with StoryTrading's 4-pillar strategy. Join the community for exclusive trade ideas!
Via Talk Markets · December 23, 2024
Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapybenzinga.com
HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement with Biosion for potential best-in-class therapies for atopic dermatitis and asthma.
Via Benzinga · December 23, 2024
This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Mondaybenzinga.com
Via Benzinga · December 23, 2024
Level Up Your Trading: Inside The 4-Pillar Strategy Behind Triple-Digit Returnstalkmarkets.com
Explore market insights and top picks with our 4-pillar strategy.
Via Talk Markets · December 18, 2024
War, Gold, And Opportunity: Uncovering Today’s Market Movestalkmarkets.com
Geopolitical tensions drive market moves as we analyze top picks.
Via Talk Markets · November 19, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 19, 2024
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developmentsbenzinga.com
Aclaris secures global rights to Biosion's BSI-045B, advancing trials for atopic dermatitis, asthma, and more. Stock surges on promising updates.
Via Benzinga · November 19, 2024
This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesdaybenzinga.com
Via Benzinga · November 19, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 28, 2024
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · October 25, 2024
Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buyingbenzinga.com
Via Benzinga · July 23, 2024
Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buyingbenzinga.com
Via Benzinga · July 8, 2024
$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buyingbenzinga.com
Via Benzinga · June 14, 2024
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · May 24, 2024
ACRS Stock Earnings: Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024investorplace.com
ACRS stock results show that Aclaris Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024
Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buyingbenzinga.com
The Dow Jones index closed lower by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · March 6, 2024
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgradesbenzinga.com
HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape.
Via Benzinga · January 22, 2024
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionwhy-com
Shares of CommScope Holding Company, Inc. (NASDAQCOMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the price target from $2.1 to $2. CommScope shares dipped 6.9% to $2.2150 on Monday.
Via Benzinga · January 22, 2024
Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarketbenzinga.com
Shares of Coherus BioSciences, Inc. (NASDAQCHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.
Via Benzinga · January 22, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · January 16, 2024
Why Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?benzinga.com
Aclaris Therapeutics leadership changes and strategic review. Preliminary unaudited data as of Dec 31, 2023, reveals approximately $182M in cash, cash equivalents, and marketable securities. Aclaris reiterates business plans for ongoing programs.
Via Benzinga · January 16, 2024
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variationsbenzinga.com
Wednesday, Aclaris Therapeutics Inc (NASDAQACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to
Via Benzinga · January 10, 2024
Crude Oil Falls 1%; Amarin Shares Spike Higherbenzinga.com
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 100 points on Wednesday. The Dow traded up 0.29% to 37,633.43 while the NASDAQ rose 0.72% to 14,965.31. The S&P 500 also rose, gaining, 0.48% to 4,779.31.
Via Benzinga · January 10, 2024